Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Ameya Harmalkar, Roshan Rao, Yuxuan Richard Xie, Jonas Honer, Wibke Deisting, Jonas Anlahr, Anja Hoenig, Julia Czwikla, Eva Sienz-Widmann, Doris Rau, Austin J. Rice, Timothy P. Riley, Danqing Li, Hannah B. Catterall, Christine E. Tinberg, Jeffrey J. Gray & Kathy Y. Wei. (2023) Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features. mAbs 15:1.
Read now
Read now
Marlena Surowka, Wolfgang Schaefer & Christian Klein. (2021) Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. mAbs 13:1.
Read now
Read now
Vala Kafil, Amir Ata Saei, Mohammad Reza Tohidkia, Jaleh Barar & Yadollah Omidi. (2020) Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds. Journal of Drug Targeting 28:10, pages 1018-1033.
Read now
Read now
Heather A. Cooke, Joe Arndt, Chao Quan, Renée I. Shapiro, Dingyi Wen, Susan Foley, Malgorzata M. Vecchi & Martin Preyer. (2018) EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies. mAbs 10:8, pages 1248-1259.
Read now
Read now
Mingyan Cao, Chunlei Wang, Wai Keen Chung, Dana Motabar, Jihong Wang, Elizabeth Christian, Shihua Lin, Alan Hunter, Xiangyang Wang & Dengfeng Liu. (2018) Characterization and analysis of scFv-IgG bispecific antibody size variants. mAbs 10:8, pages 1236-1247.
Read now
Read now
Thomas Van Blarcom, Kevin Lindquist, Zea Melton, Wai Ling Cheung, Chris Wagstrom, Dan McDonough, Cendy Valle Oseguera, Sheng Ding, Andrea Rossi, Shobha Potluri, Purnima Sundar, Steven Pitts, Marina Sirota, Meri Galindo Casas, Yu Yan, Jeffrey Jones, Zygy Roe-Zurz, Surabhi Srivatsa Srinivasan, Wenwu Zhai, Jaume Pons, Arvind Rajpal & Javier Chaparro-Riggers. (2018) Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies. mAbs 10:2, pages 256-268.
Read now
Read now
Nazzareno Dimasi, Ryan Fleming, Kris F. Sachsenmeier, Binyam Bezabeh, Carl Hay, Jincheng Wu, Erin Sult, Saravanan Rajan, Li Zhuang, Peter Cariuk, Andrew Buchanan, Michael A. Bowen, Herren Wu & Changshou Gao. (2017) Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain. mAbs 9:3, pages 438-454.
Read now
Read now
Ulrich Brinkmann & Roland E. Kontermann. (2017) The making of bispecific antibodies. mAbs 9:2, pages 182-212.
Read now
Read now
Melissa L. Geddie, Neeraj Kohli, Dmitri B. Kirpotin, Maja Razlog, Yang Jiao, Tad Kornaga, Rachel Rennard, Lihui Xu, Birgit Schoerberl, James D. Marks, Daryl C. Drummond & Alexey A. Lugovskoy. (2017) Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. mAbs 9:1, pages 58-67.
Read now
Read now
Amita Datta-Mannan, Johnny E. Croy, Linda Schirtzinger, Stacy Torgerson, Matthew Breyer & Victor J. Wroblewski. (2016) Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys. mAbs 8:5, pages 969-982.
Read now
Read now
Tamara J. van Steeg, Kirsten Riber Bergmann, Nazzareno Dimasi, Kris F. Sachsenmeier & Balaji Agoram. (2016) The application of mathematical modelling to the design of bispecific monoclonal antibodies. mAbs 8:3, pages 585-592.
Read now
Read now
Songmao Zheng, Sheri Moores, Stephen Jarantow, Jose Pardinas, Mark Chiu, Honghui Zhou & Weirong Wang. (2016) Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. mAbs 8:3, pages 551-561.
Read now
Read now
Yariv Mazor, Anna Hansen, Chunning Yang, Partha S Chowdhury, Jihong Wang, Geoffrey Stephens, Herren Wu & William F Dall’Acqua. (2015) Insights into the molecular basis of a bispecific antibody's target selectivity . mAbs 7:3, pages 461-469.
Read now
Read now
Xiufeng Wu, Arlene J Sereno, Flora Huang, Steven M Lewis, Ricky L Lieu, Caroline Weldon, Carina Torres, Cody Fine, Micheal A Batt, Jonathan R Fitchett, Andrew L Glasebrook, Brian Kuhlman & Stephen J Demarest. (2015) Fab-based bispecific antibody formats with robust biophysical properties and biological activity. mAbs 7:3, pages 470-482.
Read now
Read now
Xiufeng Wu, Arlene J Sereno, Flora Huang, Kai Zhang, Micheal Batt, Jonathan R Fitchett, Dongmei He, Heather L Rick, Elaine M Conner & Stephen J Demarest. (2015) Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. mAbs 7:2, pages 364-376.
Read now
Read now
Megan Jo Miller, Kevin C Foy, Jay P Overholser, Rita Nahta & Pravin TP Kaumaya. (2014) HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. OncoImmunology 3:11.
Read now
Read now
Michael J Gramer, Ewald TJ van den Bremer, Muriel D van Kampen, Amitava Kundu, Peter Kopfmann, Eric Etter, David Stinehelfer, Justin Long, Tom Lannom, Esther H Noordergraaf, Jolanda Gerritsen, Aran F Labrijn, Janine Schuurman, Patrick HC van Berkel & Paul WHI Parren. (2013) Production of stable bispecific IgG1 by controlled Fab-arm exchange. mAbs 5:6, pages 962-973.
Read now
Read now
Palanisamy Kanakaraj, Bridget A. Puffer, Xiao-Tao Yao, Spandana Kankanala, Ernest Boyd, Rutul R. Shah, Geping Wang, Dimki Patel, Rajesh Krishnamurthy, Shashi Kaithamana, Rodger G. Smith, David W. LaFleur, Carlos F. Barbas III, David M. Hilbert, Peter A. Kiener & Viktor V. Roschke. (2012) Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. mAbs 4:5, pages 600-613.
Read now
Read now
Roland Kontermann. (2012) Dual targeting strategies with bispecific antibodies. mAbs 4:2, pages 182-197.
Read now
Read now
Vivek Subbiah, Laura S Angelo & Razelle Kurzrock. (2011) Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver – Will it hit the moving target?. Expert Opinion on Investigational Drugs 20:11, pages 1471-1477.
Read now
Read now
Stephen J. Demarest, Kandasamy Hariharan & Jianying Dong. (2011) Emerging antibody combinations in oncology. mAbs 3:4, pages 338-351.
Read now
Read now
Articles from other publishers (48)
Emily Maria Ploeg, Isabel Britsch, Anne Paulien van Wijngaarden, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Douwe Freerk Samplonius & Wijnand Helfrich. (2023) A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer. Cancers 15:14, pages 3651.
Crossref
Crossref
Jing Hu, Qian Yang, Zhongyu Yue, Boting Liao, Huijuan Cheng, Wenqi Li, Honghua Zhang, Shuling Wang & Qingchang Tian. (2023) Emerging advances in engineered macrophages for tumor immunotherapy. Cytotherapy 25:3, pages 235-244.
Crossref
Crossref
Jia Kang, Zanzan Guo, Haoqi Zhang, Rongqi Guo, Xiaofei Zhu & Xiaofang Guo. (2022) Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer. International Journal of Molecular Sciences 23:18, pages 10382.
Crossref
Crossref
Chang-ling Gu, Hai-xia Zhu, Lan Deng, Xiao-qing Meng, Kai Li, Wei Xu, Le Zhao, Yue-qin Liu, Zhen-ping Zhu & Hao-min Huang. (2021) Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition. Acta Pharmacologica Sinica 43:3, pages 672-680.
Crossref
Crossref
Amita Datta-Mannan, Robin Brown, Stephanie Key, Paul Cain & Yiqing Feng. (2021) Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules. Antibodies 11:1, pages 2.
Crossref
Crossref
Emily M. Ploeg, Xiurong Ke, Isabel Britsch, Mark A.J.M. Hendriks, Femke A. Van der Zant, Schelto Kruijff, Douwe F. Samplonius, Hao Zhang & Wijnand Helfrich. (2021) Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. Cancer Letters 521, pages 109-118.
Crossref
Crossref
Nishant Mohan, Xiao Luo, Yi Shen, Zachary Olson, Atul Agrawal, Yukinori Endo, David S. Rotstein, Lorraine C. Pelosof & Wen Jin Wu. (2021) A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action. Cancers 13:5, pages 1027.
Crossref
Crossref
Noelia Blanco, Ambrose J. Williams, Danming Tang, Dejin Zhan, Shahram Misaghi, Robert F. Kelley & Laura C. Simmons. (2020) Tailoring translational strength using Kozak sequence variants improves bispecific antibody assembly and reduces product‐related impurities in CHO cells. Biotechnology and Bioengineering 117:7, pages 1946-1960.
Crossref
Crossref
Amita Datta-Mannan, Robin M. Brown, Jonathan Fitchett, Aik Roy Heng, Deepa Balasubramaniam, Jennifer Pereira & Johnny E. Croy. (2019) Modulation of the Biophysical Properties of Bifunctional Antibodies as a Strategy for Mitigating Poor Pharmacokinetics. Biochemistry 58:28, pages 3116-3132.
Crossref
Crossref
Ho Young Lee, Edward Contreras, Ames C. Register, Qiang Wu, Kathleen Abadie, Khristofer Garcia, Pin Yee Wong & Guoying Jiang. (2019) Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies. Scientific Reports 9:1.
Crossref
Crossref
Subhabrata Majumder, Wei Wang & Arun Alphonse Ignatius. (2019) Impact of Buffers on Colloidal Property and Aggregation Propensities of a Bispecific Antibody. Journal of Pharmaceutical Sciences 108:3, pages 1139-1147.
Crossref
Crossref
Jijie Gu, Andrew McCluskey & Tariq Ghayur. 2017. Protein Therapeutics. Protein Therapeutics
229
270
.
Thorsten Gantke, Michael Weichel, Carmen Herbrecht, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Markus Eser, Thomas Müller, Remko Griep, Vera Molkenthin, Eugene A Zhukovsky & Martin Treder. (2017) Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. Protein Engineering, Design and Selection 30:9, pages 673-684.
Crossref
Crossref
Yang Chen & Yan Xu. (2017) Pharmacokinetics of Bispecific Antibody. Current Pharmacology Reports 3:3, pages 126-137.
Crossref
Crossref
K. Ilker Sen, Wilfred H Tang, Shruti Nayak, Yong J Kil, Marshall Bern, Berk Ozoglu, Beatrix Ueberheide, Darryl Davis & Christopher Becker. (2017) Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery. Journal of the American Society for Mass Spectrometry 28:5, pages 803-810.
Crossref
Crossref
Hai-Ying Cao, Xiao-Fang Guo, Xiao-Fei Zhu, Sai-Sai Li & Yong-Su Zhen. (2017) A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer. Oncology Reports.
Crossref
Crossref
Xiao-Fang Guo, Xiao-Fei Zhu, Hai-Ying Cao, Gen-Shen Zhong, Liang Li, Bao-Guo Deng, Ping Chen, Pei-Zhen Wang, Qing-Fang Miao & Yong-Su Zhen. (2017) A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer. Oncotarget 8:16, pages 27286-27299.
Crossref
Crossref
Abdullah F. U. H. Saeed, Rongzhi Wang, Sumei Ling & Shihua Wang. (2017) Antibody Engineering for Pursuing a Healthier Future. Frontiers in Microbiology 8.
Crossref
Crossref
Aleksandra M Ochnik & Robert C Baxter. (2016) Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer. Endocrine-Related Cancer 23:11, pages R527-R550.
Crossref
Crossref
Suparna Paul, Judy Connor, Tom Nesspor, Peter Haytko, Ken Boakye, Mark L. Chiu & Haiyan Jiang. (2016) An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants. Protein Expression and Purification 121, pages 133-140.
Crossref
Crossref
Kathryn E. TillerPeter M. Tessier. (2015) Advances in Antibody Design. Annual Review of Biomedical Engineering 17:1, pages 191-216.
Crossref
Crossref
Yanni Zhu, Sung Hugh Choi & Khalid Shah. (2015) Multifunctional receptor-targeting antibodies for cancer therapy. The Lancet Oncology 16:15, pages e543-e554.
Crossref
Crossref
Caitrin Crudden, Marina Ilic, Naida Suleymanova, Claire Worrall, Ada Girnita & Leonard Girnita. (2015) The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?. Growth Hormone & IGF Research 25:1, pages 2-12.
Crossref
Crossref
Hong Yan Liu, Pavel Zrazhevskiy & Xiaohu Gao. (2014) Solid-Phase Bioconjugation of Heterobifunctional Adaptors for Versatile Assembly of Bispecific Targeting Ligands. Bioconjugate Chemistry 25:8, pages 1511-1516.
Crossref
Crossref
Ron D. Jachimowicz, Sven Borchmann & Achim Rothe. (2014) Multi-Specific Antibodies for Cancer Immunotherapy. BioDrugs 28:4, pages 331-343.
Crossref
Crossref
Dongwook Kim, Adam D. Friedman & Rihe Liu. (2014) Tetraspecific ligand for tumor-targeted delivery of nanomaterials. Biomaterials 35:23, pages 6026-6036.
Crossref
Crossref
Leonard Girnita, Claire Worrall, Shin-Ichiro Takahashi, Stefan Seregard & Ada Girnita. (2013) Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cellular and Molecular Life Sciences 71:13, pages 2403-2427.
Crossref
Crossref
Wei Zhao, Kris Sachsenmeier, Lanju Zhang, Erin Sult, Robert E. Hollingsworth & Harry Yang. (2014) A New Bliss Independence Model to Analyze Drug Combination Data. SLAS Discovery 19:5, pages 817-821.
Crossref
Crossref
Dan Lu & Zhenping Zhu. 2014. Human Monoclonal Antibodies. Human Monoclonal Antibodies
185
213
.
Hye-Ji Choi, Ye-Jin Kim, Sangho Lee & Yong-Sung Kim. (2013) A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor Activity. Molecular Cancer Therapeutics 12:12, pages 2748-2759.
Crossref
Crossref
R Castoldi, V Ecker, L Wiehle, M Majety, R Busl-Schuller, M Asmussen, A Nopora, U Jucknischke, F Osl, S Kobold, W Scheuer, M Venturi, C Klein, G Niederfellner & C Sustmann. (2013) A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene 32:50, pages 5593-5601.
Crossref
Crossref
Hannah Byrne, Paul J. Conroy, James C. Whisstock & Richard J. O’Kennedy. (2013) A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends in Biotechnology 31:11, pages 621-632.
Crossref
Crossref
Roy van der Meel, Sabrina Oliveira, Isil Altintas, Raimond Heukers, Ebel H. E. Pieters, Paul M. P. van Bergen en Henegouwen, Gert Storm, Wim E. Hennink, Robbert J. Kok & Raymond M. Schiffelers. (2013) Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways. Molecular Pharmaceutics 10:10, pages 3717-3727.
Crossref
Crossref
Aran F. LabrijnJoyce I. MeestersBart E. C. G. de GoeijEwald T. J. van den BremerJoost NeijssenMuriel D. van KampenKristin StrumaneSandra VerploegenAmitava Kundu, Michael J. Gramer, Patrick H. C. van BerkelJan G. J. van de Winkel, Janine SchuurmanPaul W. H. I. Parren. (2013) Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proceedings of the National Academy of Sciences 110:13, pages 5145-5150.
Crossref
Crossref
Edmund A. Rossi, Chien-Hsing Chang, Thomas M. Cardillo & David M. Goldenberg. (2012) Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties. Bioconjugate Chemistry 24:1, pages 63-71.
Crossref
Crossref
S.-R. Kuo, L. Wong & J.-S. Liu. (2012) Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Engineering Design and Selection 25:10, pages 561-570.
Crossref
Crossref
Rebecca Croasdale, Katharina Wartha, Juergen M. Schanzer, Klaus-Peter Kuenkele, Carola Ries, Klaus Mayer, Christian Gassner, Martina Wagner, Nikolaos Dimoudis, Sylvia Herter, Christiane Jaeger, Claudia Ferrara, Eike Hoffmann, Lothar Kling, Wilma Lau, Roland F. Staack, Julia Heinrich, Werner Scheuer, Jan Stracke, Christian Gerdes, Ulrich Brinkmann, Pablo Umana & Christian Klein. (2012) Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition. Archives of Biochemistry and Biophysics 526:2, pages 206-218.
Crossref
Crossref
Roberto Ronca, Patrizia Benzoni, Angela De Luca, Elisabetta Crescini & Patrizia Dell’Era. (2012) Phage Displayed Peptides/Antibodies Recognizing Growth Factors and Their Tyrosine Kinase Receptors as Tools for Anti-Cancer Therapeutics. International Journal of Molecular Sciences 13:4, pages 5254-5277.
Crossref
Crossref
Stefanie Claudia Pohl, Steffi Schwarz, André Frenzel & Thomas Schirrmann. (2012) A Cassette Vector System for the Rapid Cloning and Production of Bispecific Tetravalent Antibodies. Antibodies 1:1, pages 19-38.
Crossref
Crossref
Ingo Schubert, Christoph Stein & Georg H. Fey. (2012) Dual-Targeting for the Elimination of Cancer Cells with Increased Selectivity. Antibodies 1:1, pages 2-18.
Crossref
Crossref
Fei Huang, Li-an Xu & Shirin Khambata-Ford. (2012) Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer. Clinical Cancer Research 18:4, pages 1156-1166.
Crossref
Crossref
. 2012. Therapeutic Antibody Engineering. Therapeutic Antibody Engineering
299
595
.
. 2012. Therapeutic Antibody Engineering. Therapeutic Antibody Engineering
265
595
.
Jeffery S. Russell & A. Dimitrios Colevas. (2012) The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck. Chemotherapy Research and Practice 2012, pages 1-13.
Crossref
Crossref
. 2012. Therapeutic Antibody Engineering. Therapeutic Antibody Engineering
459
595
.
Ranee Mehra, Ilya G. Serebriiskii, Roland L. DunbrackJr.Jr., Matthew K. Robinson, Barbara Burtness & Erica A. Golemis. (2011) Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates 14:6, pages 260-279.
Crossref
Crossref
Joseph A. Ludwig, Salah-Eddine Lamhamedi-Cherradi, Ho-Young Lee, Aung Naing & Robert Benjamin. (2011) Dual Targeting of the Insulin-Like Growth Factor and Collateral Pathways in Cancer: Combating Drug Resistance. Cancers 3:3, pages 3029-3054.
Crossref
Crossref
Wolfgang SchaeferJörg T. RegulaMonika BähnerJürgen Schanzer, Rebecca Croasdale, Harald DürrChristian GassnerGuy GeorgesHubert KettenbergerSabine Imhof-JungManfred Schwaiger, Kay G. StubenrauchClaudio Sustmann, Markus Thomas, Werner Scheuer & Christian Klein. (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proceedings of the National Academy of Sciences 108:27, pages 11187-11192.
Crossref
Crossref